<a href="https://www.fiercebiotech.com/biotech/avalos-phase-2-win-fuels-pursuit-abbvie-despite-placebo-headwind" hreflang="en">Avalo’s phase 2 skin disease win fuels pursuit of AbbVie despite placebo headwind</a>
Avalo Therapeutics achieved positive results in a phase 2 trial for its hidradenitis suppurativa candidate, abdakibart, prompting plans to advance to phase 3 despite a placebo-adjusted response rate of 16.9%, which fell short of its initial target. The company's stock rose significantly following the announcement, indicating investor optimism as Avalo prepares to secure funding for further studies.
Avalo Therapeutics' advancement to a phase 3 trial for their hidradenitis suppurativa candidate, despite not meeting their 20% placebo-adjusted response target, signals a strategic move worth monitoring, especially given the stock price surge. This development underscores the importance of trial design and enrollment strategies in overcoming high placebo response rates, providing a lesson in risk management for biotech trials. Avalo's plan to raise $375 million for further research highlights a potential investment opportunity as they push forward in the competitive inflammatory disease space.